Korean J Urol.  2008 Apr;49(4):343-349.

The Clinical Effects of Amitriptyline on the Nocturia of Patients with Benign Prostatic Hyperplasia

• You SH
• Jeong HJ

Abstract

PURPOSE: We evaluated the effects of amitiptyline, as one of the first-line therapies, on the nocturia of patients with benign prostatic hyperplasia (BPH).
MATERIALS AND METHODS
Between June 2005 and December 2006, 50 patients completed this study(Group I=20, Group II=14, Group III=16). Group I was treated with doxazocin 4mg, group II was treated with doxazocin 4mg and tolterodine 4mg and the third group was treated with doxazocin 4mg and amitriptyline 10mg. We measured the treatment efficacy, the clinical parameters and we examined three days of the voiding diaries at baseline and after 4 weeks of treatment, respectively.
RESULTS
After 4 weeks of treatment, all the patients had significant improvement for the International Prostate Symptom Score(IPSS) and the quality of life(QoL) score among the clinical parameters and they also showed improvement of their frequency of micturition per 24 hours, per night(nocturnal frequency) among the voiding diary parameters(p<0.05). For the post-treatment comparison of the nocturnal frequency, there was a significant difference between group I and group II as well as between group I and group III(p<0.05), and there was no difference between group II and group III(p>0.05). Although there was 1 case of mild dry-mouth in group II and 1 case of mild dry-mouth and drowsiness in group III, none of the patient dropped out due to side effects.
CONCLUSIONS
We found significant improvement in the IPSS, the QoL score and the nocturnal frequency after treatment with amitriptyline 10mg. Therefore, amitriptyline 10mg would be helpful as a first-line therapy for BPH patients with nocturia.

Keyword

Amitriptyline; Nocturia; Prostatic hyperplasia

MeSH Terms

Amitriptyline
Benzhydryl Compounds
Cresols
Humans
Nocturia
Phenylpropanolamine
Prostate
Prostatic Hyperplasia
Sleep Stages
Treatment Outcome
Urination
Tolterodine Tartrate
Amitriptyline
Benzhydryl Compounds
Cresols
Phenylpropanolamine

Figure

• 

  Fig. 1 Comparison of nocturnal frequency between each group. Note the significant improvement after treatment in groups II and III (p=0.043, p=0.001) and there was no indifference between groups II and III (p=0.101) at post-treatment. *: baseline (p=0.669), †: 4 weeks (p=0.001) by the Kruskall-Wallis test.

Reference

1. Barker JC, Mitteness LS. Nocturia in the elderly. Gerontologist. 1988. 28:99–104.

2. Sommer P, Nielsen KK, Bauer T, Kristensen ES, Hermann GG, Steven K, et al. Voiding patterns in men evaluated by a questionnaire survey. Br J Urol. 1990. 65:155–160.

3. Hetta J, Rimon R, Almqvist M. Mood alterations and sleep. Ann Clin Res. 1985. 17:252–256.

4. Lindberg E, Janson C, Gislason T, Bjornsson E, Hetta J, Boman G. Sleep disturbances in a young adult population: can gender differences be explained by differences in psychological status? Sleep. 1997. 20:381–387.

5. Kim ET, Lee SI, Lee KS. The etiology and classification of nocturia in adults. Korean J Urol. 2001. 42:1075–1079.

6. Weiss JP, Blaivas JG, Stember DS, Chaikin DC. Evaluation of the etiology of nocturia in men: the nocturia and nocturnal bladder capacity indices. Neurourol Urodyn. 1999. 18:559–565.

7. Joung JY, Park JK, Park CH, Lee JG, Chung BH, Hong SJ, et al. The role of alpha 1(A) adrenoceptor antagonist tamsulosin for the treatment of patients with benign prostatic hyperplasia: the effect on lower urinary tract symptoms and nocturia. Korean J Urol. 2006. 47:1–6.

8. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004. 3:46–53.

9. Kaplan SA, Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology. 2006. 68:328–332.

10. Steers WD, Barrett DM, Wein AJ. Gillenwater JY, Grayhack JT, Howards SS, Mitchell ME, editors. Voiding dysfunction: diagnosis, classification and management. Adult and pediatric urology. 2002. 4th ed. Philadelphia: Lippincott williams & wilkins;1115–1216.

11. van Kerrebroeck P, Abrams P, Chaikin D, Donovan J, Fonda D, Jackson S, et al. The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002. 21:179–183.

12. Andersson JL, Onoe H, Hetta J, Lidstrom K, Valind S, Lilja A, et al. Brain networks affected by synchronized sleep visualizes by positron emission tomography. J Cereb Blood Flow Metab. 1998. 18:701–715.

13. Irwin M, McClintick J, Costlow C, Fortner M, White J, Gillin JC. Partial night sleep deprivation reduces natural killer and cellular immune responses in humans. FASEB J. 1996. 10:643–653.

14. Brown R, Pang G, Husband AJ, King MG. Suppression of immunity to influenza virus infection in the respiratory tract following sleep disturbance. Reg Immunol. 1089. 2:10.

15. Broman JE, Lundh LG, Hetta J. Insufficient sleep in the general population. Neurophysiol Clin. 1996. 26:30–39.

16. Bruskewitz RC, Larsen EH, Madsen PO, Dorflinger T. 3-year followup of urinary symptoms after transurethral resection of the prostate. J Urol. 1986. 136:613–615.

17. Yoshimura K, Ohara H, Ichioka K, Terada N, Matsui Y, Terai A, et al. Nocturia and benign prostatic hyperplasia. Urology. 2003. 61:786–790.

18. Homma Y, Yamaguchi T, Kondo Y, Horie S, Takahashi S, Kitamura T. Significance of nocturia in the International Prostate Symptom Score for benign prostatic hyperplasia. J Urol. 2002. 167:172–176.

19. Weiss JP, Blaivas JG. Nocturia. J Urol. 2000. 163:5–12.

20. Hanno PM, Buehler J, Wein AJ. Use of amitriptyline in the treatment of interstitial cystitis. J Urol. 1989. 141:846–848.

21. Kirkemo AK, Miles BJ, Peters JM. Use of amitriptyline in interstitial cystitis. J Urol. 1990. 143:Suppl. 279A. abstract 364.

22. Lee DH, Park CH, Kim CI. The clinical effects of amitriptyline in patients with urinary frequency and chronic pelvic pain syndrome. Korean J Urol. 2001. 42:615–620.

23. Kim HW, Seo SI, Ko JS, Jung JH, Lee JY. Incidence of overactive bladder in benign prostatic hyperplasia and the efficacy of combination therapy of alpha blocker with tolterodine. Korean J Urol. 2003. 44:1006–1010.

24. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006. 175:999–1004.

25. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006. 296:2319–2328.

26. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003. 169:2253–2256.

27. Witjes WP, Rosier PF, Caris CT, Debruyne FM, de la Rosette JJ. Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis. Urology. 1997. 49:197–205.

28. Hanno PM, Wein AJ. Medical treatment of interstitial cystitis (other than Rimso-50/Emiron). Urology. 1987. 29:4 Suppl. 22–26.

29. Hanno PM. Amitriptyline in the treatment of interstitial cystitis. Urol Clin North Am. 1994. 21:89–91.

30. Pranikoff K, Constantino G. The use of amitriptyline in patients with urinary frequency and pain. Urology. 1998. 51:5A Suppl. 179–181.